

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

ABBVIE INC.,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. _____
	)	
TEVA PHARMACEUTICALS, INC. and	)	
TEVA PHARMACEUTICAL INDUSTRIES	)	
LTD.,	)	
	)	
Defendants.	)	

**SUPPLEMENTAL INFORMATION FOR PATENT CASES  
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiff hereby provides the information below with respect to the deadlines set forth in  
21 U.S.C. § 355(j):

Date Patentee(s) Received Notice:	February 14, 2023
Date NDA Holder Received Notice:	February 14, 2023
Date of Expiration of U.S. Patent No. 11,542,239	July 23, 2039
Hatch-Waxman Regulatory Exclusivity Deadline:	January 23, 2026

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

*/s/ Jeremy A. Tigan*

OF COUNSEL:

Jennifer H. Roscetti  
Danielle A. Duszczyszyn  
William B. Raich  
Constance P. Lee  
Ryan V. McDonnell  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP  
901 New York Avenue, NW  
Washington, DC 20001-4431  
(202) 408-4000

---

Jack B. Blumenfeld (#1014)  
Jeremy A. Tigan (#5239)  
Megan E. Dellinger (#5739)  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
(302) 658-9200  
jblumenfeld@morrisnichols.com  
jtigan@morrisnichols.com  
mdellinger@morrisnichols.com

*Attorneys for Plaintiff AbbVie Inc.*

March 30, 2023